Postepidemic Analysis of Rift Valley Fever Virus Transmission in Northeastern Kenya: A Village Cohort Study

被引:47
作者
LaBeaud, A. Desiree [1 ,2 ]
Muiruri, Samuel [3 ]
Sutherland, Laura J. [2 ]
Dahir, Saidi [3 ]
Gildengorin, Ginny [1 ]
Morrill, John [4 ]
Muchiri, Eric M. [3 ]
Peters, Clarence J. [4 ]
King, Charles H. [2 ]
机构
[1] Childrens Hosp Oakland Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA USA
[2] Case Western Reserve Univ, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA
[3] Minist Publ Hlth & Sanitat, Div Vector Borne & Neglected Trop Dis, Nairobi, Kenya
[4] Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX USA
基金
美国国家卫生研究院;
关键词
SAUDI-ARABIA; EPIDEMIC; OUTBREAK; VACCINE; SPECTRUM; SAFETY;
D O I
10.1371/journal.pntd.0001265
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: In endemic areas, Rift Valley fever virus (RVFV) is a significant threat to both human and animal health. Goals of this study were to measure human anti-RVFV seroprevalence in a high-risk area following the 2006-2007 Kenyan Rift Valley Fever (RVF) epidemic, to identify risk factors for interval seroconversion, and to monitor individuals previously exposed to RVFV in order to document the persistence of their anti-RVFV antibodies. Methodology/Findings: We conducted a village cohort study in Ijara District, Northeastern Province, Kenya. One hundred two individuals tested for RVFV exposure before the 2006-2007 RVF outbreak were restudied to determine interval anti-RVFV seroconversion and persistence of humoral immunity since 2006. Ninety-two additional subjects were enrolled from randomly selected households to help identify risk factors for current seropositivity. Overall, 44/194 or 23% (CI95%:17%-29%) of local residents were RVFV seropositive. 1/85 at-risk individuals restudied in the follow-up cohort had seroconverted since early 2006. 27/92 (29%, CI95%:20%-39%) of newly tested individuals were seropositive. All 13 individuals with positive titers (by plaque reduction neutralization testing (PRNT80)) in 2006 remained positive in 2009. After adjustment in multivariable logistic models, age, village, and drinking raw milk were significantly associated with RVFV seropositivity. Visual impairment (defined as <= 20/80) was much more likely in the RVFV-seropositive group (P<0.0001). Conclusions: Our results highlight significant variability in RVFV exposure in two neighboring villages having very similar climate, terrain, and insect density. Among those with previous exposure, RVFV titers remained at >1:40 for more than 3 years. In concordance with previous studies, residents of the more rural village were more likely to be seropositive and RVFV seropositivity was associated with poor visual acuity. Raw milk consumption was strongly associated with RVFV exposure, which may represent an important new focus for public health education during future RVF outbreaks.
引用
收藏
页数:9
相关论文
共 35 条
[1]   Ocular complications of Rift Valley fever outbreak in Saudi Arabia [J].
Al-Hazmi, A ;
Al-Rajhi, AA ;
Abboud, EB ;
Ayoola, EA ;
Al-Hazmi, M ;
Saadi, R ;
Ahmed, N .
OPHTHALMOLOGY, 2005, 112 (02) :313-318
[2]   Epidemic rift valley fever in Saudi Arabia: A clinical study of severe illness in humans [J].
Al-Hazmi, M ;
Ayoola, EA ;
Abdurahman, M ;
Banzal, S ;
Ashraf, J ;
El-Bushra, A ;
Hazmi, AE ;
Abdullah, M ;
Abbo, H ;
Elamin, A ;
Al-Sammani, E ;
Gadour, M ;
Menon, C ;
Hamza, M ;
Rahim, I ;
Hafez, M ;
Jambavalikar, M ;
Arishi, H ;
Aqeel, A .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (03) :245-252
[3]  
Alexander R. A., 1951, Journal of the South African Veterinary Medical Association, V22, P105
[4]   Rift Valley fever encephalitis [J].
Alrajhi, AA ;
Al-Semari, A ;
Al-Watban, J .
EMERGING INFECTIOUS DISEASES, 2004, 10 (03) :554-555
[5]  
Ayoola Ayobanji E., 2003, American Journal of Gastroenterology, V98, pS92, DOI 10.1016/S0002-9270(03)01040-2
[6]   Rift Valley fever virus [J].
Bird, Brian H. ;
Ksiazek, Thomas G. ;
Nichol, Stuart T. ;
MacLachlan, N. James .
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2009, 234 (07) :883-893
[7]  
*CDC, 2010, CDC VIR HEM FEV FACT
[8]  
*CDC, 2007, RIFT VALL FEV VIR HE, P1
[9]  
Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P982
[10]  
Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P1065